2023
Maternal serum concentrations of per- and polyfluoroalkyl substances and childhood acute lymphoblastic leukemia
Jones R, Madrigal J, Troisi R, Surcel H, Öhman H, Kivelä J, Kiviranta H, Rantakokko P, Koponen J, Medgyesi D, McGlynn K, Sampson J, Albert P, Ward M. Maternal serum concentrations of per- and polyfluoroalkyl substances and childhood acute lymphoblastic leukemia. Journal Of The National Cancer Institute 2023, 116: 728-736. PMID: 38092046, PMCID: PMC11077307, DOI: 10.1093/jnci/djad261.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaLymphoblastic leukemiaOdds ratioChildhood acute lymphoblastic leukemiaFinnish Maternity CohortMaternal serum concentrationsMaternal serum levelsCommon childhood cancerConfidence intervalsConditional logistic regressionFirst trimester samplesChild sexPerfluorooctane sulfonic acidMaternal smokingGestational ageSerum levelsDiagnosis ageSerum concentrationsChildhood cancerCalendar periodFull-term offspringChildhood leukemiaMother's ageImmunotoxic propertiesLogistic regressionPrediagnostic serum concentrations of per‐ and polyfluoroalkyl substances and risk of papillary thyroid cancer in the Finnish Maternity Cohort
Madrigal J, Troisi R, Surcel H, Öhman H, Kivelä J, Kiviranta H, Rantakokko P, Koponen J, Medgyesi D, Kitahara C, McGlynn K, Sampson J, Albert P, Ward M, Jones R. Prediagnostic serum concentrations of per‐ and polyfluoroalkyl substances and risk of papillary thyroid cancer in the Finnish Maternity Cohort. International Journal Of Cancer 2023, 154: 979-991. PMID: 37902275, PMCID: PMC11286200, DOI: 10.1002/ijc.34776.Peer-Reviewed Original ResearchFinnish Maternity CohortPapillary thyroid cancerThyroid cancerOdds ratioPrediagnostic serum concentrationsPrediagnostic serum levelsConfidence intervalsCase-control studyConditional logistic regressionThyroid cancer riskPapillary thyroid cancer riskPerfluorononanoic acidPerfluorodecanoic acidPerfluorohexane sulfonic acidHigh exposure levelsMedian ageSerum levelsSerum concentrationsCalendar periodCancer riskBirth cohortThyroid glandLogistic regressionCancerClear association
2022
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness
Lind M, Copin R, McCarthy S, Coppi A, Warner F, Ferguson D, Duckwall C, Borg R, Muenker M, Overton J, Hamon S, Zhou A, Cummings D, Ko A, Hamilton J, Schulz W, Hitchings M. Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. The Journal Of Infectious Diseases 2022, 227: 663-674. PMID: 36408616, DOI: 10.1093/infdis/jiac453.Peer-Reviewed Original ResearchConceptsVaccine effectivenessImmune evasionDelta infectionVE estimatesSecond doseTest-negative case-control studySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Whole-genome sequencingCOVID-19 vaccine effectivenessRespiratory syndrome coronavirus 2Syndrome coronavirus 2Case-control studyCoronavirus 2Calendar periodDelta variantInfectionDoseEvasionDaysLow effectivenessImmunityVariants
2021
HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs
McGinnis KA, Skanderson M, Justice AC, Akgün KM, Tate JP, King JT, Rentsch CT, Marconi VC, Hsieh E, Ruser C, Kidwai‐Khan F, Yousefzadeh R, Erdos J, Park LS. HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs. Journal Of The International AIDS Society 2021, 24: e25810. PMID: 34713585, PMCID: PMC8554215, DOI: 10.1002/jia2.25810.Peer-Reviewed Original ResearchConceptsVeterans AffairsClinic visitsCohort studyVL testARV coverageCOVID-19 pandemicVeterans Aging Cohort StudyHIV healthcare deliveryNationwide cohort studyAging Cohort StudyViral load testsDifferentiated service deliveryHealthcare deliveryHIV careMost patientsPharmacy recordsVL testingCalendar periodHealthcare encountersOverall healthARVVirtual healthcareVirtual visitsVisitsService deliveryAssessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States. JAMA Dermatology 2021, 157: 59-65. PMID: 33146688, PMCID: PMC7643047, DOI: 10.1001/jamadermatol.2020.4102.Peer-Reviewed Original ResearchConceptsMerkel cell carcinomaBirth cohort effectsCell carcinomaIncidence rateCalendar periodBirth cohortPatient ageNew casesCohort effectsEnd Results Program databaseCross-sectional retrospective studyLongitudinal cohort studyHigh incidence rateAge-adjusted ratesRisk factor exposureRecent birth cohortsCohort studyCarcinoma incidenceRetrospective studyNeuroendocrine cancerAge effectsProgram databaseCohort analysisMAIN OUTCOMECarcinoma
2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survival
2014
An easy, fast, effective tool to monitor the incidence of type 1 diabetes among children aged 0–4 years in Italy: the Italian Hospital Discharge Registry (IHDR)
Vichi M, Iafusco D, Galderisi A, Stazi M, Nisticò L. An easy, fast, effective tool to monitor the incidence of type 1 diabetes among children aged 0–4 years in Italy: the Italian Hospital Discharge Registry (IHDR). Acta Diabetologica 2014, 51: 287-294. PMID: 24473635, DOI: 10.1007/s00592-014-0556-4.Peer-Reviewed Original ResearchConceptsType 1 diabetes incidenceType 1 diabetesHospital Discharge RegistryDiabetes incidenceDischarge RegistryFirst hospitalizationFirst hospitalization ratesPublic health purposesIncident hospitalizationHospitalization ratesCalendar periodPrevalent casesFirst episodeHospitalizationDiabetesOverall populationNational ratesIncidenceAge rangeYear residentsHealth purposesNational dataRegistryRecord linkage procedureChildren
1990
Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons
Vlahov D, Lee H, Taylor E, Canavaggio M, Canner C, Burczak J, Saah A. Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 531-535. DOI: 10.1097/00126334-199003050-00010.Peer-Reviewed Original ResearchHuman T-Lymphotropic Virus Type I/IIExact testIncoming male inmatesHIV-1 serostatusIntravenous drug usersPrevalence of HTLVFisher's exact testYears of ageSame calendar periodWestern blot techniqueType I/IIEpidemiological serosurveyMale inmatesScope of infectionRisk groupsCalendar periodHIV-1Drug usersHTLVMaryland prisonsBlot techniqueRoutine operational proceduresAntibodiesYear of entrySerostatusAntibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons
Vlahov D, Lee H, Taylor E, Canavaggio M, Canner C, Burczak J, Saah A. Antibody to Human T-Lymphotropic Virus Type I/II (HTLV-I/II) Among Male Inmates Entering Maryland Prisons. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 531-535. PMID: 1969961, DOI: 10.1097/00126334-199005000-00010.Peer-Reviewed Original ResearchConceptsHuman T-Lymphotropic Virus Type I/IIExact testIncoming male inmatesHIV-1 serostatusIntravenous drug usersPrevalence of HTLVFisher's exact testYears of ageSame calendar periodWestern blot techniqueType I/IIEpidemiological serosurveyScope of infectionMale inmatesCalendar periodRisk groupsHIV-1Drug usersHTLVMaryland prisonsChi 2Blot techniqueRoutine operational proceduresAntibodiesYear of entry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply